
US biotech companies Bambusa Therapeutics and Aspen Neuroscience have filed for initial public offerings (IPOs), seeking funding as they prepare further trials of bispecific antibodies and a patient-derived cell therapy for Parkinson’s disease, respectively.
Both submitted registration statements to the Securities and Exchange Commission (SEC) on October 9. Their proposed offerings add to a queue that includes US drug developers City Therapeutics, Iambic Therapeutics and Lycia Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze